Internet Drug
Pharmaceutical News & Information; Updated Daily Since 1998

Drug Coupons Database
Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here

Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media & Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- Drug Wonks
- World Of DTC
ΏYour Link Here?
Let's Trade

Pharmaceutical News Harvest (TM) 

10/2 Sticker Shock at Price for New Melanoma Combo
Bristol-Myers Cancer Drug Combination to Cost $256,000 a Year .... The price is for a patient that takes four doses of the combination -- which includes a standard dose of the drug Yervoy and a lower dose of Opdivo -- every three weeks, followed by a higher dose of Opdivo alone every two weeks .... Bloomberg
See also: FDA approves costly Bristol-Myers drug combo for melanoma [Reuters]

10/2 FTC Blasts 'Product-Hopping'
Drugmaker Tactic to Block Generics May Violate Law, FTC Says .... Brand-name drugmakers sometimes make insignificant formulation changes to their products just before patents are about to run out and as generics are about to come to the market. Those formulation tweaks let the drugmaker switch patients to the new brand-name drug, or to make improved product claims .... Bloomberg

10/2 Which Pharma Companies Are Jacking Up Prices the Most?
Massive, unexpected drug price increases are happening all the time .... The average price increase for products made by specialty pharmaceutical companies, which concentrate on pricier drugs, was 16% in 2012, 29% in 2013, 22% in 2014, and 19% so far in 2015 .... Quartz

10/2 Eteplirsen Maker Borrows Patients from Other Studies to Support Benefit
Sarepta gets creative in bolstering its case for quick eteplirsen approval .... Pulling together a control arm by selecting patients who had been enrolled in other studies--a rare maneuver--the biotech sought to reassure doubters that its drug provided a significant, long-lasting benefit with clear biomarker evidence that the drug usually worked as expected .... Fierce Biotech
See also: Sarepta Unveils New Data to Make Stronger Case for Duchenne Drug Approval [The Street]

10/2 Afrezza Manufacturer Says Goodbye to More Workers
MannKind engages in third round of layoffs in Danbury .... Sales of Afrezza--which was approved by the U.S. Food and Drug Administration last year and hit the market in February--so far have been lackluster, with marketing partner Sanofi reporting total sales of about $5.5 million as of June 30. .... NewsTimes

10/2 When All Studies Are Published, Not Just Ones with Positive Results, A New Picture Emerges
Effectiveness of Talk Therapy Is Overstated, a Study Says .... Treatments like cognitive behavior therapy and interpersonal therapy are indeed effective, the analysis found, but about 25 percent less so than previously thought. .... NY Times

10/2 Less than Half of Those with HIV Getting Any Treatment
UN: HIV Patients Should Start Treatment Immediately .... The new guidance means that all 37 million people with HIV globally should be offered immediate treatment, a prospect that may be unrealistic in poor countries, where many patients are still unable to get medicines. Last year, only about 15 million people with HIV were being treated. .... NY Times

10/2 Jazz's Defibrotide to Get Early Decision
FDA grants priority review to defibrotide for hepatic veno-occlusive disease .... The FDA granted priority review to defibrotide, an investigational agent in development for treatment of patients with hepatic veno-occlusive disease who have evidence of multiorgan dysfunction after hematopoietic stem cell transplantation. .... Healio

10/2 Wanna Pair of Beestungs? Allergan Has Got You Covered
FDA Approves Lip Filler That Lasts A Year — Will Kylie Jenner Do It? .... A study found that within 3 months, 79% of subjects showed a "meaningful improvement in lip fullness after treatment [using Juvederm Ultra XC] — results can still be seen up to one year." .... Hollywood Life

10/2 Remember Willie Horton? Campaign Will Make Shkreli the Face of Pharma
Not done yet, Hillary Clinton airs pharma-focused ad starring Turing CEO .... In a new campaign ad airing this week, Clinton makes Shkreli the "star," interspersing an image of his face from a Today Show interview with newscast snippets about his outrageous Daraprim price hike .... Fierce Pharma

10/2 Internet Drug News Fast Takes:
For seniors, hearing trouble linked to greater risk of death
Teva to Buy Rimsa for About $2.3 Billion
Merck sells Kuvan rights back to BioMarin
Pharma Times
Two-Day FDA Advisory Committee Meeting to Address Drug Compounding Questions
Regulatory Focus
Geisinger to close on AtlantiCare acquisition, beefs up New Jersey presence
Health Care Finance News

10/1 FDA Taking Hard Look at Chinese Pharma Manufacturing
Trashed Tests Put FDA on Notice as China Pushes Drug Exports .... China has a growing drug industry, and one that increasingly wants to make not just raw ingredients but finished drugs for export. Yet there are currently only two FDA drug inspectors in the country, overseeing about 700 facilities involved in drugmaking. .... Bloomberg

10/1 Remember the PBMs Throwing Hissy Fits About PCSK9 Inhibitors? Never Mind, They Turned Down All the PreAuths
New cholesterol drugs won't be budget busters: Express Scripts .... Everett Neville, a vice president of Express Scripts, said Express Scripts and insurers had rejected a surprisingly high number of prescriptions for the two injectable drugs, Praluent from Regeneron Pharmaceuticals and Sanofi, and Amgen Inc's Repatha. .... Reuters

10/1 MacArthur Genius Finds the Patent System Drives Investment in the Wrong Sorts of Drugs
What Cures Are We Missing Out On? .... The study found that drug-company investment increased with the stage of cancer targeted. In essence, pharma R&D labs work much harder trying to get the sickest patients a few more months of life than trying to treat tumors at an earlier stage, which could add years to patients' lives .... Bloomberg

10/1 More Buck, Less Bang
Cancer Drugs Aren't As Cost-Effective As They Used To Be .... In the mid-nineties, cancer drugs generally provided an extra year of life for less than $100,000, most new treatments typically provide a year of life for as much as $150,000 or even $200,000 .... Forbes/Peter Ubel

10/1 What the FDA Means by 'Breakthrough' Isn't What Regular Folks Expect
Word 'breakthrough' dramatically affects perceptions of a new drug's effectiveness .... Some 42% of the women who took compounded hormones thought that "natural" or "bioidentical" hormones are safer than other types of hormones, even though there are more than 30 tested and FDA-approved hormones for menopause, including many that are similar to human hormones. .... Medical Xpress

10/1 Industry-Financed Docs Pooh-Pooh Low-T Cardio 'Signal'
What risk? Physician group questions FDA view on Testosterone drugs .... A leading physicians group is questioning claims that testosterone replacement therapy increases the risk of heart disease — contradicting concerns expressed by the Food and Drug Administration .... Pharmalot

10/1 Ocrelizumab, for MS, Forecast at $656 Million Sales in 2019
Roche poised for MS coup with success in hard-to-treat progressive form .... The company has announced positive Phase III data for the drug in primary progressive multiple sclerosis, a less common form of the disease--affecting about 10% to 20% of sufferers--that right now remains untreated .... Fierce Pharma Marketing

10/1 Many Women Prefer 'Natural' Hormones to FDA-Approved Therapies
One-third of hormone users at menopause take unapproved, untested compounded drugs .... Some 42% of the women who took compounded hormones thought that "natural" or "bioidentical" hormones are safer than other types of hormones, even though there are more than 30 tested and FDA-approved hormones for menopause, including many that are similar to human hormones. .... The North American Menopause Society

10/1 'Trajectory Modeling' Gives Early Warning of Nonadherence
CVS study: Early medication-fill patterns can predict future adherence .... A patient's future medication-adherence behavior can be predicted by examining the patient's patterns of medication fills in the first few months after beginning chronic therapy .... American Pharmacy News

10/1 What Gets You in Hot Water with the FDA?
Omitting risk info in ads is top reason for FDA warning .... About 60% of FDA warning letters and untitled letters issued to pharmaceutical companies over the past two years cited omitted risk information in promotional materials .... MM&M

10/1 Internet Drug News Fast Takes:
Bayer restructures its operations, drops Bayer Healthcare group
Increasing calcium intake 'does not improve bone health of seniors'
Medical News Today
Study Links Asthma to Low Levels of Gut Bacteria in Newborns
Wall Street Journal
Placebo power: Depressed people who respond to fake drugs get the most help from real ones
University of Michigan Health System
Pfizer Boosts Its Guidance, Suggesting Better Times May Be Coming
Motley Fool

9/30 Average Part D Monthly Premiums Will Break $40 Barrier
Medicare drug plan prices set to rise in 2016, some by a lot .... More than 15 million people enrolled in the top 10 Medicare "Part D" prescription drug plans will face average premium hikes of 8 percent next year .... CNBC

9/30 Billions at Stake on Immunotherapy — Who Do You Bet On?
Which Big Pharma Will Grab the Lion's Share of the Cancer Immunotherapy Market? .... Cancer immunotherapy is one of the hottest areas of cancer research these days, and the market looks to be worth billions. .... Motley Fool

9/30 Pain Pills Walking Out the Door at MGH
Mass. General to pay $2.3 million over drug thefts .... According to the settlement agreement, one nurse identified as J.S. stole 14,492 pills, and a second nurse, identified as J.Z. 1, pilfered 1,429 tablets.... most of the pills were the prescription painkiller oxycodone .... Boston Globe

9/30 Leading Cancer Doc Calls for Paying for Value
The drug price conundrum: a Q&A with Memorial Sloan Kettering's Dr. Peter B. Bach .... "Pharma is walking a line where they want total pricing control and they want to be opaque like any other for-profit company, but they want to use rationales that are in the public interest." .... Fortune

9/30 Lixisenatide (Lyxumia) Filed
FDA will review Sanofi's diabetes drug lixisenatide .... In the 5,000-patient-plus GetGoal clinical programme, the once-daily shot worked as well as twice-daily exentide (Lilly's Byetta) in lowering blood sugar levels with a similar safety profile .... Pharma Times

9/30 No Good Answers on Warnings for DTCA
NEJM: FDA's proposed risk-disclosure guidelines still aren't enough .... "After 30 years of DTCA, it's not clear that advertising is the best medium for communicating risk information, but marketers should at least be required to try to communicate risk information as effectively as they do their promotional messages." (Jeremy A. Greene, M.D., Ph.D., and Elizabeth S. Watkins, Ph.D.) .... Fierce Pharma Marketing

9/30 Alexion vs. Canada
Canada is trying to cut the price of a $525,000-a-year drug, and is getting sued for it .... Alexion's suit fundamentally challenges Canada's right to compel companies to lower the prices on patented drugs. If it succeeds, prices could rise dramatically in the country. .... Quartz

9/30 Medication Therapy Management Model Will Pay Insurers for Better Adherence
CMS tests model to increase drug adherence on Part D plans .... Participating plans will be able to offer different medication therapy management services based on enrollees' level of medication-related risk, with interventions tailored to those enrollees' specific barriers to improvement. .... Modern Healthcare

9/30 Kardashians Tested at Pathway Genomics, the Company in Hot Water with the FDA
Kardashian trio tested for genetic cancerous gene in San Diego .... Kim Kardashian, sister Khloe and their mother Kris Jenner — joined by celebrity doc Paul Nassif and a camera crew — journeyed to San Diego to get tested for a rare, genetic and often fatal cancer mutation .... NY Daily News

9/30 Oncotype DX Validated in NEJM Study
Breast Cancer Gene Test Helps Predict Who Can Skip Chemo .... For patients who fell into the test's low-risk category, 99 percent didn't develop metastatic breast cancer five years after surgery, even though they didn't have chemotherapy. The overall survival rate among this group was 98 percent .... NPR

9/30 Internet Drug News Fast Takes:
U.S. states urge FDA to ensure warnings on liquid nicotine products
Lilly/Incyte unveil more PhIII success for RA drug baricitinib
Pharma Times
Aspirin may double survival for cancer patients
Medical News Today
Arsenic found in many US red wines, but health risks depend on total diet
University of Washington
A Health-Care Model in Coal Country
Wall Street Journal

Metformin Linked to Increased Height in Children, Teens
Endocrijnology Advisor
Clinton Proposes Drugmakers Fund Their Own Generic Competition
Roche gets jump on rivals in race for progressive multiple sclerosis treatment
Biotech stocks dive as lawmakers take aim at Valeant for Isuprel and Nitropress jumbo price hikes
3 Biotech Stocks Short-Sellers Have Targeted the Most
Motley Fool
Antibacterial Soap Is No More Effective Than Regular Soap, So Why Are We Still Buying It?
Mylan Launches Generic Invega® Tablets
Mylan Press Release

9/29 Sanofi Makes Arrangements With Lilly To Bring Out Biosim Lantus Pen
Sanofi settles lawsuit enabling rival to Lantus insulin …  settlement ends all lawsuits worldwide between the companies over patents for Lantus SoloStar. Lily will pay undisclosed royalties to Sanofi in exchange for a license to certain Sanofi patents that would have kept Basaglar off the U.S. market until April 2025 …[AP]
Sanofi, Eli Lilly reach deal on insulin product …  Lilly said that Sanofi has granted the company a royalty-bearing license to make the drug and sell it globally in Kwikpens … [Reuters]

How Novo Plans To Market Tresiba (Insulin Degludec)
- Dosing convenience appears to be big part of message
Novo combats talk of insulin price war with 'moderate premium' on brand-new Tresiba … Novo is counting on early adoption by smaller, "more permissive" healthcare plans … raft of data on its heart safety--and some head-to-head studies against Sanofi's longtime mainstay, Lantus…. hired hundreds of new reps in anticipation of Tresiba approval  … [Fierce Pharma]
Novo Nordisk outlines Tresiba's differences to best Toujeo … will utilize the "vast majority" of its sales force to engage both primary-care physicians and specialists in a balanced approach …  marketing duel with Toujeo will likely come down to formulary access, saying that negotiations with pharmacy benefit managers will likely determine which product will take the majority of market share …[MM&M]
Novo shares jump ahead of its largest ever drug launch … As an ultra-long acting product … The labeling did come out largely as we had expected. We intend to launch Tresiba in the U.S. market with a moderate premium …[Reuters]

Advocacy Group Hypes $5,000 Co-Pay Relief For HIV Patients
- Hope for HIV patients walloped with copays
Co-Pay Relief Program Unveils New Financial Assistance for Patients with HIV, AIDS or Those Being Treated to Prevent the HIV Virus … has provided more than $230 million in financial assistance to more than 140,000 patients who would have been otherwise unable to afford their pharmaceutical co-payments, co-insurance and/or deductibles …[ Patient Advocate Foundation]

PhRMA Gets New Top Lobbyist
Drug Companies Hire New Lobbyist to Answer Critics … hose a new top lobbyist Friday to help pharmaceutical companies defend themselves against criticism from patients, doctors and government officials who say they are charging exorbitant prices … For the last 10 years, Mr. Ubl has been the top lobbyist for medical device makers. He has led efforts to persuade Congress to repeal a tax on medical devices imposed by the Affordable Care Act …[NY Times]

How much more does the U.S. pay for drugs? Up to 10 times more, report says
How much more does the U.S. pay for drugs? Up to 10 times more, report says …  Gleevec in the U.S. is $6,214, while the same drug costs $989 in New Zealand …  Copaxone runs at an average price of $3,903 in the U.S. compared with $862 in England …  Nexium runs at about $215 in the U.S., compared with $60 in Switzerland and just $23 in the Netherlands …[Fierce Pharma]
Related: U.S. cancer drug prices up to 3X higher than in Europe: Study …[Fierce Pharma]

Cocktail Of 3 Off-The-Shelf Antibiotics Knocks Out MRSA In Study
Combo of 3 Antibiotics Can Kill Deadly Staph Infections … The three drugs -- meropenem, piperacillin and tazobactam -- are from a class of antibiotics called beta-lactams that has not been effective against MRSA for decades.????????????? … combination appears to prevent MRSA from becoming resistant to it, … all bacteria eventually develop resistance to antibiotics, but this trio buys us some time, potentially a significant amount of time …[Drug Discovery & Devolpment]

Fast Takes
Why Prescription Drug Price Reform Will Probably Fail
Motley Fool
In A First, Kidney Cancer Drug Extends Survival
The Best-Selling Drugs in the World By 2020
Motley Fool
Allergan Launches Generic Version of INVEGA® (paliperidone)
Allergan Press Release
Report: J&J had plan to block more FDA restrictions on Tylenol

9/28 NOVO:FDA Approves Tresiba (Insulin Degludec) Long Acting Insulin
- Also Ryzodeg 70/30 fixed combo with aspart
FDA Approves Long-Lasting Insulin Drugs Tresiba and Ryzodeg … Because of the drug's extended coverage, patients do not need to take it the same time each day as with other basal insulins, leading some to call it the "Sunday-sleeping-in insulin … [Medscape]
Novo Nordisk Receives FDA Approval for Tresiba® (insulin degludec injection) for Adults with Type 1 and Type 2 Diabetes … available in the FlexTouch® pen, which has no push-button extension, and will be offered in two concentrations enabling maximum doses of 80 units and 160 units per single injection, respectively.1 Tresiba® also offers other patient benefits such as eight weeks  of in-use time at room temperature …[NASDAQ]
See Also: Tresiba PI
Editor's Note: Tresiba is available as U100 and U200.  In our opinion the label a disappointment to NOVO - there are no comparative claims regarding  hypoglycemia, nocturnal hypoglycemia or efficacy versus glargine.  This is remarkable considering  media releases from last year proclaiming degludec had lower rates of hypoglycemia than glargine.  What is different from glargine is that the maximum dose per shot is 160 units (as opposed to 80 units with glargine if you use the U200 version) and Tresiba can be stored at room temperature for 8 weeks, twice as long as Lantus or Toujeo.  The press release hints at a possible marketing  plan when it states, "Tresiba® provides a long duration of action beyond 42 hours.  While patients are encouraged to take their insulin at the same time each day, Tresiba® allows patients to dose at any time of the day".   

9/28 How Marketing Turned the EpiPen Into a Billion-Dollar Business
- Mylan's marketing turned the allergy device into a must-have.
How Marketing Turned the EpiPen Into a Billion-Dollar Business …  textbook case in savvy branding combined with a massive public awareness campaign on the dangers of child allergies. Along the way, EpiPen's wholesale price rose roughly 400 percent from about $57 each when Mylan acquired the product …[Bloomberg]
Editor's Note: Pharmaceutical marketing 101.  If you are in marketing, you need to read this and share it with your colleagues. 

9/28 Scrooge CEO Of Pharma: Investigative Report Reveals More Screwball Greed Moves
- investigation uncovers more ethically questionable tactics 
Biotech exec Martin Shkreli has history of tough tactics …  In 2010, while running his hedge fund, Shkreli wrote a letter to the FDA urging the agency to turn down an application from MannKind, a company he was shorting … In 2011, Shkreli then turned his attention to Navidea and its cancer diagnostic, called Lymphoseek -- this time going so far as to a file a "citizen's petition … Simultaneously shorting a stock and petitioning the FDA, as Shkreli did with Navidea, was "highly unusual … [Statnews via]

9/28 Death Of A (Pharmaceutical) Salesman?
- Yes and no?
Has the era of the super successful pharma sales rep really come to an end? … what's happening now is not the death of an entire profession, but rather the decline of an outdated model … however,  well-trained, digitally savvy pharmaceutical sales representatives will continue to be in demand well into the foreseeable future …[BiopharmaDive]
Editor's Note: I have been hearing the same bullshit story (that there will be no more drug reps soon) since I started as a drug rep in 1985.  They will always need reps.  Maybe fewer of them or bigger territories but there will always be drug reps.

9/25 Expect Big Changes from Califf
FDA Nominee Driven by "Data, Data, Data" .... The current clinical research system, Dr. Califf said, was "well-intentioned but flawed. It's too slow, too expensive, not reliable, doesn't answer questions that matter to most patients, and is unattractive to clinicians and administrators that need to work in it. Otherwise, it's a great system." .... Genetic Engineering & Biotechnology News

9/25 PBMs Due for Shakeup and Overhaul
How the national drug debate is changing the pharmacy benefit business .... Industry observers say stand-alone PBMs like Express Scripts face an uphill financial battle. Aside from dealing with high drug prices, many companies have used most of the weapons in their arsenal to keep drug costs down .... Modern Healthcare

9/25 FDA Slams 'Liquid Biopsy' Test
Startup's Cancer Test for the Healthy May Harm Public, FDA Says .... The FDA wrote to Pathway Genomics Corp. on Sept. 21 about the test, which retails for as much as $699. Patients get the test ordered by their doctor or one working for Pathway, then the company analyzes a blood sample for circulating traces of cancer. .... Bloomberg

9/25 Panel Recommends Sticking to Indication for PCSK9 Inhibitors
Top U.S. doctors say pricey cholesterol drugs best for limited group .... Top U.S. heart doctors on a panel at Harvard School of Public Health recommend that newly developed cholesterol treatments that cost more than $14,000 per year are best used for the small group of patients for which they have been approved, at least for now .... Reuters

9/25 Shkreli Puts Drug Industry in 2016 Election Spotlight
Turing Pharma price hike debacle tars entire pharma industry's reputation .... How much damage can one person do? In the case of the pharma industry this week, the answer was quite a lot. .... Fierce Pharma

9/25 You're Probably Sick of Shkreli by Now, But Here He Is, Up Close and Personal
My Lunch With Shkreli: What We Should Learn From Pharma's Latest Monster .... Other companies have jacked up prices just as much as his firm, Turing, with no consequences other than soaring stock prices. Hillary Clinton's reforms? It's unlikely they'd make a difference. .... Forbes/Matthew Herper

9/25 Powerful Diabetes Preventative May Be Sitting on Your Nightstand Already
Taking Blood Pressure Drugs at Night May Help Prevent Type 2 Diabetes .... For every 14-point decrease in a person's average sleeping systolic blood pressure, they experienced a 30 percent reduction in their risk of developing type 2 diabetes .... HealthDay

9/25 Broader OTC Naloxone
CVS To Sell Overdose Reversal Drug Without A Prescription In 12 More States .... The announcement will affect CVS pharmacies in Arkansas, California, Minnesota, Mississippi, Montana, New Jersey, North Dakota, Pennsylvania, South Carolina, Tennessee, Utah and Wisconsin. .... Huffington Post

9/25 At High Risk for Diabetes? Diet Exercise Better than Medication
Over long term, diet and exercise are best to prevent diabetes .... In a head-to-head comparison over 15 years, diet and exercise outperformed the drug metformin in preventing people at high risk for diabetes from developing the disease .... Reuters

9/25 Januvia Defense Plan
Here's How Merck Plans to Protect Billions of Dollars in Sales .... Merck has intriguing new diabetes drugs in development that could blunt any market share risk following Eli Lilly's positive phase 3 trial results for Jardiance. .... Motley Fool

9/25 36% of Plaque Psoriasis Get Biologics
Study Looks at Costs for Moderate to Severe Plaque Psoriasis .... Most patients prescribed one or more medications; six-month total direct costs per patient $11,291 .... HealthDay News

9/25 Internet Drug News Fast Takes:
Millennium Health Said in Bankruptcy Talks Before Settlement
The Miracle Sugar Substitute The FDA Won't Let You Have
Atlas Obscura
World's largest reinsurer ready to insure against FDA actions
Fierce Pharma Manufacturing
Novartis' top scientist is stepping down after 13 years, making way for a Harvard luminary
Fierce Biotech
Inflammatory response may fan the flame of dietary fats' role in obesity-related diseases
University of Vermont College of Medicine

9/24 FDA's Unapproved-Drugs Initiative Culprit Behind Huge Price Spikes for Old Drugs
The little-known FDA program that's driving drug prices higher .... In many of these cases, the new manufacturers had done little to alter, much less improve, the traditional drugs before claiming FDA-mandated exclusivity periods ranging from three to seven years .... LA Times

9/24 Shkreli Backs Down But Won't Set a Figure
Turing CEO Says He'll Lower Price of Antibiotic From $750 a Pill .... Martin Shkreli, chief executive officer of Turing Pharmaceuticals AG, said he would lower the price of the drug Daraprim after being criticized for boosting it 50-fold to $750 a pill .... Bloomberg

9/24 Bariatric Surgery Proposed as Diabetes Treatment
Weight-loss surgery may not increase health costs for diabetes .... Weight loss surgery may be a cost-effective way of lowering blood sugar for many diabetics, not just those who are severely obese .... Reuters

9/24 Employees Get Growing Share of Health Care Tab
Survey: Employees are facing modest premium increases—but skyrocketing out-of-pocket costs .... The average deductible for health plans among all workers with employer-sponsored coverage has reached $1,077 this year, compared with $646 in 2010 and just $303 in 2006. .... Advisory Board

9/24 Kalydeco Improved by Changing 1 Atom
Concert shares soar as it bests Vertex cystic fibrosis drug in Phase 1 trial .... By replacing a single hydrogen atom with deuterium in a 3-year-old cystic fibrosis drug developed by Vertex Pharmaceuticals, Lexington-based Concert Pharmaceuticals says it was able to show the altered version works better in a small, early-stage clinical trial .... Boston Business Journal

9/24 EpiPen a Now Billion Dollar Business (Video Link)
How Mylan Turned EpiPen Into a Must-Have .... Mylan purchased the EpiPen brand from Merck KGaA in 2007 and proceeded to build the brand into a billion-dollar business .... Bloomberg Video

9/24 How Many Banners Will Ad-Blockers Block?
Apple's ad blocking heats up debate, but what does it mean for pharma? .... The rise in ad blocking will likely result in more partnerships in which pharma companies work with publishers or even professional organizations to co-create healthcare content that consumers want or need (Klick Health VP of strategy Michael Spitz) .... Fierce Pharma Marketing

9/24 A List of Older Drugs Still Selling Well
Some pharma senior citizens still work overtime .... 20 pharma brands with a mean age of over 66 that, rather than enjoying a well-earned retirement, are each pulling in over half a billion dollars' worth of sales on average .... EP Vantage

9/24 More Drugs in Development Making It Across the Finish Line
Analysis shows pharma is getting better at R&D .... From 2010 to 2014, one out of every 13 drugs in phase-I development came to market—compared to one of 19 phase-I drug candidates making it from 2007 to 2011 .... MM&M

9/24 But Are There Too Many Drugs on Expedited Approval Tracks?
Concerns over FDA's increasing use of expedited development and approval pathways .... Over the past 20 years, there has been a statistically significant increase of 2.6% per year in the number of drugs qualifying for the FDA's expedited drug development and approval programs .... Medical Xpress

9/24 Internet Drug News Fast Takes:
Non-antibotic drug shows promise in deadly C. difficile infections
Kythera seeks permission to test baldness drug in humans
Pharma Times
Clinton Aims to Tackle Out-Of-Pocket Health Care Costs
NY Times
FDA launches patient engagement committee
Health Care IT News
Combo Drug May Calm Agitation in Alzheimer's Patients
HealthDay News

9/23 IOM Bombshell: Errors in Diagnosis Account for 10% of Patient Deaths
Errors In Diagnosis Are Common And Will Take Teamwork To Fix .... Almost every American will experience an error in diagnosis at some point in life. But the problem has taken a back seat to other patient safety concerns .... NPR Health Blog

9/23 Clinton Platform: No Tax Deductions for DTC Ads, Medicare Can Negotiate, Out of Pocket Cap, Reimportation
Clinton proposes $250 monthly cap on prescription drug costs .... The largest pharmaceutical companies are collectively earning $80 billion to $90 billion per year at higher margins than other industries while average Americans struggle to pay for medicine, Clinton's campaign said .... Reuters

9/23 Hillary Will Make Sure You Don't Forget About Martin Shkreli for the Next Year or Two
Controversial Drug CEO Was Accused of Serious 'Harassment' .... The pharmaceutical company boss under fire from Hillary Clinton and many others for jacking up the price of the drug Daraprim 5,500 percent overnight allegedly engaged previously in a bizarre campaign of "harassment" of a former employee and his immediate family .... NBC News

9/23 Meanwhile in Indiana, Licensor Pulls Drug Rights After Price is Jacked Up Sky High
Nonprofit Gets Back Drug and Reverses 18-Fold Increase in Price .... A nonprofit in Indiana has dropped the price of a drug for multi-drug resistant tuberculosis roughly 90% after re-acquiring rights to the medicine from Rodelis Therapeutics, the latest sign of a growing outcry over skyrocketing costs for rare disease treatments .... Bloomberg

9/23 In US, Drug Prices Often Exceed 600x Manufacturing Cost
Exclusive: Americans overpaying hugely for cancer drugs .... The United States pays more than double the price charged in Europe for tyrosine kinase inhibitors (TKIs), a potent class of cancer pills with fewer side effects than chemotherapy .... Reuters

9/23 Lonsurf Approved
FDA approves new advanced colorectal cancer pill .... Approval came on the back of data from the Phase III RECOURSE trial, which showed a significant improvement in overall survival in patients taking Lonsurf compared to placebo, and a reduction in the risk of death of 32%. .... Pharma Times

9/23 17,000 Women Harmed by Essure; FDA Calls a Panel Discussion
FDA advisers to weigh concerns over Bayer's Essure contraceptive .... Some 17,000 women who had the device implanted and claim it has hurt them are members of the Facebook group "Essure Problems," run by Angela Lynch, who herself experienced problems with Essure. Complaints voiced by the women include chronic pain, heavy bleeding, fatigue and skin allergies .... Reuters

9/23 Chronic Care Management a Boon for Docs with Medicare Patients
How Medicare's 'chronic care management' payments could affect primary care .... Practices could see substantial increases in annual revenue (ranging from $69,665 to $77,295 in year one) if they used registered nurses (RNs) or licensed practical nurses (LPNs) to conduct the required annual wellness visit and used auxiliary staff to do some of the month-to-month management .... Reuters

9/23 Poor Adherence? Send a Text
A text message a day may keep the doctor away .... After six months, patients who got four texts a week generally had more success reducing their weight, blood pressure, cholesterol and tobacco use than the people who didn't. .... Reuters

9/23 PFE Hypes Cancer Pipeline
Pfizer says it could be leader in cancer with many new drugs .... Today, Pfizer has eight approved cancer medicines, four of them launched in the last four years. It's running late-stage patient tests on five of those drugs for additional uses, has three other drugs in late-stage testing — usually the last round before seeking regulators' approval — and has 14 other drug programs in early stages .... AP/Yahoo

9/23 AZN to Let Outsiders Rummage Through its Compound Closet
AstraZeneca taps crowd sourcing to find cancer drug cocktails .... The data includes around 10,000 tested combinations measuring the ability of drugs to destroy cancer cell lines from different tumor types and it will be matched with genomic information from the Wellcome Trust Sanger Institute .... Reuters/Yahoo

9/23 Fake Drug Trade Crosses Borders; US Not Safe
The Fake Drug Industry Is Exploding, and We Can't Do Anything About It .... Task forces are finding more fake drugs every year. Interpol's flagship pharmaceutical investigation, Operation Pangea, for example, says it seized 2.4 million fake and illicit pills in 2011; in 2015, the total number of pills and other medications that officials seized jumped to 20.7 million. .... Newsweek

9/23 Internet Drug News Fast Takes:
Heron Therapeutics' pain drug meets mid-stage trial goal
fMRI May Take Guesswork Out of Schizophrenia Rx
HealthDay News
Wherever You Go, Your Personal Cloud Of Microbes Follows
NPR Health Blog

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 9/28/15

If you feel that your intellectual property being infringed
e-mail the webmaster and we will remove the content. 

The information on this site is not meant as medical advice.  Information provided on the site is meant to complement and not replace any advice or information from a health professional.

I am not a doctor - I am a pharmacist.  If you have any medical questions please consult your medical doctor or similar medical practitioner. 

We never answer drug or health related questions so please don't e-mail us with your drug related questions.

If you have a question about a drug that you are taking or if you think you are experiencing a side effect from a drug that you are taking you must get in touch with the doctor who prescribed the drug or the pharmacist who dispensed it to you, not us.

The information contained on this web site is for your information only.  You should never take a drug without a doctor's prescription.   Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

It's foolish to start taking a medicine or stop taking a medicine on your own based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.


Corey Nahman Registered Pharmacist

We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.
2.  Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3.  Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4. Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5.  Justifiability
This site shall at all times back up claims relating to benefits and performance.
6  Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7.  Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  All advertisements shall be clearly distinguished from content.